Organization Profile
← Back to all OrganizationsAddress
No address has been added to this Organization
VENTURE
OncoSTING (Private)
OncoSTING is developing recombinant STING agonist
immunotherapies including OS-101 and others.
STING agonists, small molecules that trigger proinflammatory innate immune responses against tumors, show promise to revolutionize cancer immunotherapy.
OS-101 is a second-generation BCG immunotherapy for bladder cancer which produces high levels of a potent STING agonist and at the same time retains the known efficacy of traditional BCG.
OncoSTING’s preclinical research and development has revealed that OS-101 is more effective than traditional BCG in multiple models of bladder cancer.
Additionally, OS-101 has an improved safety profile compared to traditional BCG in preclinical studies.
OS-101 is a second-generation BCG immunotherapy for bladder cancer which produces high levels of a potent STING agonist and at the same time retains the known efficacy of traditional BCG.
OncoSTING’s preclinical research and development has revealed that OS-101 is more effective than traditional BCG in multiple models of bladder cancer.
Additionally, OS-101 has an improved safety profile compared to traditional BCG in preclinical studies.
Resource Type
There are no Keywords associated with this Resource. If you help manage this Resource, become a Verified Manager of any of its Hosting Organizations to make edits to the details shown here.
Jobs
Events
Relationships
Claim Org
© Copyright 2025
Scraping of this website is prohibited